Skip to main content

Table 3 Potentially eligible registered trials identified by AFFIRM’s systematic review

From: Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM)

Study name & principal investigator Identified through Participants Intervention & control Outcomes Comment re: inclusion in IPDMA
EPPI McLintock Ongoing RCT (New Zealand) ANZCTR registry ACTRN12609000699268 Prior PE or SGA Enoxaparin 40 mg vs standard care PE, SGA Recruitment ongoing
HEPEPE Haddad Ongoing RCT (France) NCT00986765 Prior severe pre-eclampsia Enoxaparin 4000 IU + ASA vs ASA PE; IUGR; abruption; perinatal death Recruitment ongoing
HOPPE Llurba Ongoing RCT (Spain) NCT01388322 Prior severe PE, SGA, loss, or abruption Enoxaparin 40 mg or 80 mg (weight-based) vsno intervention PE; IUGR; abruption; fetal death Recruitment ongoing
  1. ASA = aspirin; IPDMA = individual patient data meta-analysis; IUGR = intrauterine growth restriction; PE = pre-eclampsia; SGA = small-for-gestational age.
  2. Trial Names:
  3. EPPI = Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction.
  4. HEPEPE = Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia (original title is French).
  5. HOPPE = Low Weight Heparin prOphylaxis for Placental Mediated Complications of PrEgnancy.